Loading
NASDAQHealthcareBiotechnology
Latest quote
$11.19
+$0.065 · +0.58%
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Previous close
$11.19
+$0.065 · +0.58%
Regular session · ET · Market data may be delayed.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Day range
Current $11.19
52-week range
Current $11.19
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
23
Expensive
Sentiment
61
Bullish
Risk
71
High Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Day range
Current $11.19
52-week range
Current $11.19
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 251K USD | 33.49M USD | 4.93M USD | 2M USD |
| Cost of goods sold | 2.6M USD | — | — | — | — |
| Gross profit | −2.6M USD | 251K USD | 33.49M USD | 4.93M USD | 2M USD |
| Research and development | 69.54M USD | 50.33M USD | 50.25M USD | 43.98M USD | 42.41M USD |
| Selling, general, and administrative | 20.27M USD | 17.21M USD | 13.91M USD | 20.78M USD | 12.86M USD |
| Operating expenses | 88.01M USD | 67.53M USD | 64.16M USD | 64.76M USD | 55.27M USD |
| Interest income | 5.96M USD | 5.35M USD | 2.54M USD | 1.29M USD | — |
| Depreciation and amortization | 2.6M USD | 2.43M USD | 2.27M USD | 1.16M USD | 248K USD |
| Operating income | −90.61M USD | −67.28M USD | −30.67M USD | −59.83M USD | −53.27M USD |
| Net income | −83.87M USD | −58.49M USD | −27.7M USD | −58.39M USD | −71.83M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$37.50
235.12% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI7.07M0.00%2.3T USD0.03%$379.73-0.32%
Vanguard Extended Market ETFVXF2.72M0.00%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 ETFIWM1.54M0.00%80.51B USD0.19%$296.01+0.28%
Simplify Propel Opportunities ETFSURI1.13M1.29%87.88M USD2.82%$20.49+0.94%
iShares Russell 2000 Value ETFIWN398.59K0.00%14.61B USD0.24%$224.62+0.40%
U.S. Micro Cap Portfolio ETFDFMC305.11K0.00%7.98B USD0.43%$60.36+0.60%
Vanguard Russell 2000 ETFVTWO263.3K0.00%17.4B USD0.06%$119.62+0.25%
iShares Micro-Cap ETFIWC175.6K0.01%1.49B USD0.60%$196.25+0.69%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMSimplify Propel Opportunities ETFSURIiShares Russell 2000 Value ETFIWNU.S. Micro Cap Portfolio ETFDFMCVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
